Bioorganic and Medicinal Chemistry Letters

Journal

Publication Venue For

  • A small diversity library of α-methyl amide analogs of sulindac for probing anticancer structure-activity relationships.  28:2136-2142. 2018
  • Diverse amide analogs of sulindac for cancer treatment and prevention.  27:4614-4621. 2017
  • Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.  27:1731-1736. 2017
  • Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.  27:2962-2966. 2017
  • Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer.  26:1237-1244. 2016
  • Hydroxychalcone inhibitors of Streptococcus mutans glucosyl transferases and biofilms as potential anticaries agents.  26:3508-3513. 2016
  • Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease.  26:5573-5579. 2016
  • Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease..  24:1472-1478. 2014
  • Synthesis and SAR of geminal substitutions at the C5′ carbosugar position of pyrimidine-derived HCV inhibitors.  22:6967-6973. 2012
  • Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.  22:5652-5657. 2012
  • Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.  22:5144-5149. 2012
  • 5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.  22:3229-3234. 2012
  • Novel substituted pyrimidines as HCV replication (replicase) inhibitors.  22:1160-1164. 2012
  • Discovery of a new molecular probe ML228: An activator of the hypoxia inducible factor (HIF) pathway.  22:76-81. 2012
  • Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.  21:5528-5532. 2011
  • Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs).  19:2001-2005. 2009
  • Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A.  18:380-385. 2008
  • Synthesis of symmetrical C- and pseudo-symmetrical O-linked disaccharide analogs for arabinosyltransferase inhibitory activity in Mycobacterium tuberculosis.  17:4527-4530. 2007
  • Analogs of the marine alkaloid makaluvamines: Synthesis, topoisomerase II inhibition, and anticancer activity.  17:2890-2893. 2007
  • Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.  16:4743-4747. 2006
  • Discover and SAR of 2-aminothiazole Inhibitors of Cyclin-dependent Kinase 5/p25 as a Potential Treatment for Alzheimer’s Disease.  14:5521-5525. 2004
  • A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ.  14:3161-3164. 2004
  • Activation and desensitization of heteromeric neuronal nicotinic receptors: Implications for non-synaptic transmission.  14:1897-1900. 2004
  • Heterocyclic aminopyrrolidine derivatives as melatoninergic agents..  13:4381-4384. 2003
  • Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain.  13:1475-1478. 2003
  • Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine..  12:3379-3382. 2002
  • Synthesis of an arabinofuranosyl disaccharide photoaffinity probe for arabinosyltransferase activity in Mycobacterium tuberculosis.  12:2749-2752. 2002
  • An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology..  11:2393-2396. 2001
  • Atropisomeric Quinazolin-4-one Derivatives are Potent Noncompetitive Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Antagonists.  11:177-181. 2001
  • Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors.  10:2427-2430. 2000
  • Salicylamide inhibitors of influenza virus fusion..  10:1649-1652. 2000
  • Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping (vol 9, pg 1901, 1999).  9:3259-3259. 1999
  • Erratum: Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping (Bioorg. Med. Chem. Lett. (1999) 9 (1901) PII: S0960894X99003182).  9:3259. 1999
  • Novel quinolizidine salicylamide influenza fusion inhibitors..  9:2177-2180. 1999
  • Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.  9:1901-1906. 1999
  • Uridine phosphorylase inhibitors: Chemical modification of benzyloxybenzyl-barbituric acid and its effects on UrdPase inhibition.  9:1477-1480. 1999
  • Homologated aza analogs of arabinose as antimycobacterial agents.  8:237-242. 1998
  • Conformationally constrained precursors to retinoic acid analogs which stabilize the 9Z-configuration.  5:953-958. 1995
  • International Standard Serial Number (issn)

  • 0960-894X
  • Electronic International Standard Serial Number (eissn)

  • 1464-3405